首页> 外文期刊>Blood cancer journal. >A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor
【24h】

A myeloma cell line established from a patient refractory to thalidomide therapy revealed high-risk cytogenetic abnormalities and produced vascular endothelial growth factor

机译:从难治性沙利度胺治疗建立的骨髓瘤细胞系显示出高危的细胞遗传学异常并产生了血管内皮生长因子

获取原文
           

摘要

Recent advances in the treatment of multiple myeloma (MM) using newly developed drugs, such as thalidomide, lenalidomide and bortezomib, have improved the survival of the patients with refractory disease. However, it remains difficult to treat certain populations of MM patients; these patients are considered high-risk cases.
机译:使用沙利度胺,来那度胺和硼替佐米等新开发的药物治疗多发性骨髓瘤(MM)的最新进展提高了难治性疾病患者的生存率。然而,仍然难以治疗某些MM患者。这些患者被认为是高危病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号